What this means
A company is testing a skin injection in healthy adults over three treatments and 70 days. No results have been posted, so we cannot yet know if it works or is safe.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 35 and over
- Where
- 1 site
The science
- Registered title
- Effectiveness and Safety of Cellbooster Shape in Healthy Subjects
- Trial ID
- NCT07636512 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Skin Aging
- What is tested
- Skin booster injection (CBS)
- Sponsor
- Suisselle
- Ages
- 35 Years to no maximum
- Dates
- First posted Jun 9, 2026 · updated Jun 9, 2026
Registry summary
SUISSELLE has developed a CE marketed (2021) HA-based superficial epidermis/dermis injection filler and skinbooster product, Cellbooster® Shape (CBS). CBS is produced using patented CHAC Technology. It consists of non-crosslinked HA with L-Carnitine and vitamin C. The device is particularly designed for reducing local puffiness by improving microcirculation and hydration.
The current post-market clinical investigation is designed to evaluate the efficacy and safety of CBS. For this purpose, healthy subjects with signs of skin aging in the face will receive a 3-session treatment and will be followed-up over 70 days after the initial injection session.
Several objective measurements of skin quality will be performed with different instruments allowing to assess skin volume, skin elasticity, skin hydration, and skin microcirculation. Subjective clinical improvement will be evaluated, as well as subject and investigator satisfactions.
The safety of the injections will be assessed by collecting the Injection Site Reactions (ISRs) and Adverse Events (AEs).
Sites (1)
- Eurofins Dermscan Pharmascan, Villeurbanne, France